Skyhawk Therapeutics gibt die Ausweitung seiner globalen zulassungsrelevanten klinischen Studie „FALCON-HD" für SKY-0515 zur Behandlung der Huntington-Krankheit auf die Vereinigten Staaten, Kanada und das Vereinigte Königreich bekannt

Skyhawk Therapeutics erhielt eine US-IND sowie CTAs für Kanada und das Vereinigte Königreich und erweitert damit die Phase-2/3-Startvorbereitungen der zulassungsrelevanten Studie FALCON-HD (004-ANZ/004-WW) gegen die Huntington-Krankheit. Die Phase-1/2-Rekrutierung ist abgeschlossen; nach 12 Monaten Behandlung zeigte SKY-0515 eine Verringerung von mHTT um 69% und von PMS1 um 26% sowie Verbesserungen beim cUHDRS, ohne die typischen Verschlechterungen des natürlichen Verlaufs. Insgesamt nehmen bereits über 175 Patienten in >10 Ländern/20+ Standorten teil—die Rekrutierung für die Phase-2/3 zulassungsrelevante Studie soll nun in den genannten Märkten beginnen.

Analysis

This is more important as a platform read-through than as a single-asset event. An oral CNS RNA-modulator with apparent biomarker plus functional signal, if replicated, would challenge the market’s assumption that meaningful HD disease modification must come from invasive delivery or gene therapy. That shifts future partnering economics: capital should migrate toward programs with scalable manufacturing, easier chronic dosing, and broader neurologist adoption, which can compress the premium for more cumbersome modalities.

The near-term market reaction likely overweights the biomarker headline and underweights translational risk. The key question over the next 1-3 months is whether the enlarged global study preserves the same directionality across a larger, more heterogeneous cohort; if it does, the company buys itself financing and BD optionality, but not yet a clean commercial narrative. The real valuation inflection is 6-18 months out, when blinded functional data either confirm that mHTT lowering maps into cUHDRS durability or expose surrogate overfitting.

Contrarianly, the consensus may be too focused on “rare disease winner” optics and not enough on commercial depth. Even a successful HD drug may remain a niche revenue stream, so the bigger prize is validating the SKYSTAR platform for follow-on CNS indications. Falsifier: any drift in safety with chronic dosing, or a phase 2/3 readout that shows biomarker suppression without functional separation versus placebo; that would likely re-rate the whole oral-RNA thesis lower.

Key Decisions for Investors

• No direct public-company trade in the issuer; treat this as a watch item for CNS/RNA platform sentiment and partnerability through the next 1-3 months.
• For speculative biotech exposure, consider a small tactical long in XBI on weakness, with a 6-12 month horizon; thesis is platform de-risking, not immediate revenue, so keep sizing modest and use a 10-15% stop if HD-related follow-through fades.
• Relative-value idea: long XBI / short IBB for 1-3 months if small-cap CNS biotech starts to reprice on oral-therapy optionality; risk is that the move stays idiosyncratic and broad biotech beta remains dominated by rates.
• Set an alert for the first global phase 2/3 efficacy/safety update; if functional endpoints fail to stay ahead of natural decline, exit any sentiment-driven exposure immediately.